Your browser doesn't support javascript.
loading
A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.
de Weger, Vincent A; Stuurman, Frederik E; Hendrikx, Jeroen J M A; Moes, Johannes J; Sawicki, Emilia; Huitema, Alwin D R; Nuijen, Bastiaan; Thijssen, Bas; Rosing, Hilde; Keessen, Marianne; Mergui-Roelvink, Marja; Beijnen, Jos H; Schellens, Jan H M; Marchetti, Serena.
Afiliação
  • de Weger VA; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Stuurman FE; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Hendrikx JJMA; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands.
  • Moes JJ; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands.
  • Sawicki E; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands; Modra Pharmaceuticals BV, Amsterdam, The Netherlands.
  • Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Nuijen B; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands.
  • Thijssen B; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands.
  • Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands.
  • Keessen M; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Modra Pharmaceuticals BV, Amsterdam, The Netherlands.
  • Mergui-Roelvink M; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Modra Pharmaceuticals BV, Amsterdam, The Netherlands.
  • Schellens JHM; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Modra Pharmaceuticals BV, Amsterdam, The Netherlands.
  • Marchetti S; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: s.marchetti@nki.nl.
Eur J Cancer ; 86: 217-225, 2017 11.
Article em En | MEDLINE | ID: mdl-29031170
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Ritonavir / Taxoides / Neoplasias Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Ritonavir / Taxoides / Neoplasias Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article